Pfizer Inc. (PFE) saw its shares decline 0.8% to $24.89 on Tuesday, underperforming the broader health-care sector, which posted gains. The drop followed the company's announcement that a critical experimental lung cancer therapy, sigvotatug vedotin, failed to meet its primary survival endpoint in a late-stage clinical study. This setback adds to the challenges Pfizer faces as it seeks to reignite growth following the decline of its COVID-era product revenues.
Drug Disappointment
The drug, an antibody-drug conjugate (ADC) designed to target tumor cells, did not demonstrate a statistically significant improvement in overall survival compared to docetaxel chemotherapy in adults with advanced non-squamous non-small cell lung cancer, a common form of the disease. The trial involved patients who had received prior treatments, with about two-thirds having only one prior therapy. Despite the miss, Pfizer noted a better trend in overall survival and progression-free survival in that subgroup, and safety was deemed manageable, consistent with earlier data.
Jeff Legos, Pfizer's chief oncology officer, acknowledged there is "more work to be done" in previously treated advanced lung cancer but expressed confidence in the drug, citing ongoing trials, including a Phase 3 study combining sigvotatug vedotin with Merck's Keytruda in first-line lung cancer. Solange Peters, a medical oncology chair at Lausanne University Hospital, highlighted a "clinically meaningful survival benefit" in second-line data and urged further investigation in earlier treatment lines.
Growth Strategy Under Pressure
The failed readout is a blow to Pfizer's strategy to bolster its oncology pipeline through the $43 billion acquisition of Seagen in 2023. The deal was intended to offset declining sales from COVID-19 vaccines and treatments, as well as patent expirations on older drugs. Pfizer shares have fallen more than 50% since early 2023, and the company is betting on new blockbusters, including obesity drugs and other oncology products, to drive growth by 2028.
Analysts remain cautious. Leerink's David Risinger, who had called the data a "major oncology catalyst," noted the drug "still has a chance" in the first-line trial, where it will be compared to Keytruda rather than docetaxel. RBC Capital Markets' Trung Huynh said the failure is "unlikely to help confidence" in the Seagen deal and flagged potential for another impairment charge. Pfizer has previously taken write-downs related to the acquisition.
Market and Earnings Context
Pfizer's stock decline occurred as the Health Care Select Sector SPDR ETF gained 1.3%, while the broader S&P 500 fell roughly 1%. Merck (MRK), which will co-test Keytruda with Pfizer's drug, rose 2.9%. The market's reaction reflects uncertainty about the drug's future, including regulatory approval, commercial adoption, and the lack of a clear biomarker link to patient response.
Investors are now focused on Pfizer's second-quarter earnings call scheduled for August 4, 2026. The company beat first-quarter profit and sales expectations in May, maintaining its 2026 revenue forecast of $59.5 billion to $62.5 billion and adjusted EPS guidance of $2.80 to $3.00. Management has pointed to obesity drugs, oncology products, and extended exclusivity for Vyndamax as potential growth drivers beyond 2028. RBC's Huynh described Pfizer as "a catalyst story, not an earnings story," underscoring the importance of pipeline developments.
The upcoming earnings call will provide further updates on the company's performance and strategic outlook. For now, the failed lung cancer trial underscores the high stakes in Pfizer's quest to replace lost COVID revenue and rebuild investor confidence.
